Lipella Pharmaceuticals

ArTara Therapeutics

This clinical-stage biopharmaceutical company develops cell therapies and replacement treatments for patients with non-muscle invasive bladder cancer and rare metabolic diseases.

UroGen Pharma

This company develops and commercialises hydrogel-based medicines for patients with urological and specialty cancers, including treatments for low-grade upper tract urothelial carcinoma and bladder cancer.

Medexus Pharmaceuticals

This company provides specialty and orphan drugs for patients and healthcare professionals treating diseases such as oncology, haematology, rheumatology, allergy and dermatology.

CG Oncology

This biopharmaceutical company develops oncolytic immunotherapies for patients with non-muscle invasive bladder cancer.

MitoImmune Therapeutics

This biotechnology firm develops mitochondrial-targeted therapies for patients with inflammatory and rare diseases, including cancer treatment side effects like oral mucositis.

Aurealis Pharma

This company develops cell and gene therapies for patients suffering from chronic wounds, cancer and inflammatory diseases.

Forma Therapeutics

This company develops medicines for patients with sickle cell disease and rare blood disorders.

Nuvectis Pharma

This biopharmaceutical company develops precision medicines and targeted small molecule therapeutics for patients with advanced cancers and other serious conditions.